Vitamin C neglect in hemodialysis: Sailing between Scylla and Charybdis

Blood Purification

Volumn 25, Issue 1, 2006, Pages 58-61

  Handelman, Garry J ^a  

^a RENAL RESEARCH INSTITUTE   (United States)

Author keywords

Hemodialysis; Oxalosis, systemic; Vitamin C

Indexed keywords

ASCORBIC ACID; ERYTHROPOIETIN; IRON;

ANEMIA; ASCORBIC ACID DEFICIENCY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; ERYTHROPOIESIS; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; NONHUMAN; OXALOSIS; PRIORITY JOURNAL; SCURVY; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; ASCORBIC ACID; ASCORBIC ACID DEFICIENCY; ERYTHROPOIESIS; FATIGUE; HUMANS; HYPEROXALURIA; ORAL HEALTH; OXALATES; RENAL DIALYSIS;

EID: 33845791546     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096399     Document Type: Conference Paper

References (39)

1. Sullivan JF, Eisenstein AB: Ascorbic acid depletion during hemodialysis. JAMA 1972;220:1697-1699.
2. Ahmed J, Weisberg LS: Hyperkalemia in dialysis patients. Semin Dial 2001;14:348-356.
3. Durose CL, Holdsworth M, Watson V, et al: Knowledge of dietary restrictions and the medical consequences of noncompliance by patients on hemodialysis are not predictive of dietary compliance. J Am Diet Assoc 2004;104:35-41.
4. Morena M, Cristol JP, Bosc JY, et al: Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 2002;17:422-427.
5. Bohm V, Tiroke K, Schneider S, et al: Vitamin C status of patients with chronic renal failure, dialysis patients and patients after renal transplantation. Int J Vitam Nutr Res 1997;67:262-266.
6. Levine M, Rumsey SC, Daruwala R, et al: Criteria and recommendations for vitamin C intake. JAMA 1999;281:1415-1423.
7. Jackson P, Loughrey CM, Lightbody JH, et al: Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995;41:1135-1138.
8. Salyer WR, Keren D: Oxalosis as a complication of chronic renal failure. Kidney Int 1973;4:61-66.
9. Friedman AH, Charles NC: Retinal oxalosis in two diabetic patients. Am J Ophthalmol 1974;78:189-195.
10. Tomson CR, Channon SM, Ward MK, et al: Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis. Nephrol Dial Transplant 1989;4:792-799.
11. Brenner B, Rector J: The Kidney, ed 4. New York, Williams & Wilkins, 2004.
12. Derman D, Sayers M, Lynch SR, et al: Iron absorption from a cereal-based meal containing cane sugar fortified with ascorbic acid. Br J Nutr 1977;38:261-269.
13. Fidler MC, Davidsson L, Zeder C, et al: Iron absorption from ferrous fumarate in adult women is influenced by ascorbic acid but not by Na2EDTA. Br J Nutr 2003;90:1081-1085.
14. Nissenson AR, Lindsay RM, Swan S, et al: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999;33:471-482.
15. Charytan C, Qunibi W, Bailie GR: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-c62.
16. Sikole A, Stojanovic A, Polenakovic M, et al: How erythropoietin affects bone marrow of uremic patients. Am J Nephrol 1997;17:128-136.
17. Lipschitz DA, Bothwell TH, Seftel HC, et al: The role of ascorbic acid in the metabolism of storage iron. Br J Haematol 1971;20:155-163.
18. Wapnick AA, Bothwell TH, Seftel H: The relationship between serum iron levels and ascorbic acid stores in siderotic Bantu. Br J Haematol 1970;19:271-276.
19. Lynch SR, Seftel HC, Torrance JD, et al: Accelerated oxidative catabolism of ascorbic acid in siderotic Bantu. Am J Clin Nutr 1967;20:641-647.
20. Kang JY: The gastrointestinal tract in uremia. Dig Dis Sci 1993;38:257-268.
21. Charytan C, Levin N, Al-Saloum M, et al: Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001;37:300-307.
22. Mircescu G, Garneata L, Capusa C, et al: Intrav enous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 2006;21:120-124.
23. Fleming LW, Hopwood D, Shepherd AN, et al: Hepatic iron in dialysed patients given intravenous iron dextran. J Clin Pathol 1990;43:119-124.
24. Van Wyck D, Anderson J, Johnson K: Labile iron in parenteral iron formulations: A quantitative and comparative study. Nephrol Dial Transplant 2004;19:561-565.
25. Danielson BG, Salmonson T, Derendorf H, et al: Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung 1996;46:615-621.
26. Seligman PA, Dahl NV, Strobos J, et al: Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy 2004;24:574-583.
27. Henderson P, Hillman R: Characteristics of iron dextran utilization in man. Blood 1969;34:357-375.
28. Overly CC, Lee KD, Berthiaume E, et al: Quantitative measurement of intraorganelle pH in the endosomal-lysosomal pathway in neurons by using ratiometric imaging with pyranine. Proc Natl Acad Sci USA 1995;92:3156-3160.
29. Gastaldello K, Vereerstraeten A, Nzame-Nze T, et al: Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 1995;10:44-47.
30. Tarng DC, Wei YH, Huang TP, et al: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999;55:2477-2486.
31. Attallah N, Osman-Malik Y, Frinak S, et al: Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 2006;47:644-654.
32. Chan D, Irish A, Dogra G: Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton) 2005;10:336-340.
33. Deicher R, Ziai F, Habicht A, et al: Vitamin C plasma level and response to erythropoietin in patients on maintenance haemodialysis. Nephrol Dial Transplant 2004;19:2319-2324.
34. Rahmati MA, Craig RG, Homel P, et al: Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 2002;40:983-989.
35. Levine M, Conry-Cantilena C, Wang Y, et al: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704-3709.
36. Khajehdehi P, Mojerlou M, Behzadi S, et al: A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps. Nephrol Dial Transplant 2001;16:1448-1451.
37. Fain O: Musculoskeletal manifestations of scurvy. Joint Bone Spine 2005;72:124-128.
38. Ching SY, Prins AW, Beilby JP: Stability of ascorbic acid in serum and plasma prior to analysis. Ann Clin Biochem 2002;39:518-520.
39. Chung WY, Chung JK, Szeto YT, et al: Plasma ascorbic acid: measurement, stability and clinical utility revisited. Clin Biochem 2001;34:623-627.